CAR-T cells targeting CD19 and CD22 for B-cell cancers
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD22) on cancer cells. It is for people with B-cell acute lymphoblastic leukemia or non-Hodgkin's lymphoma that has come back or did not respond to previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have B-cell acute lymphoblastic leukemia or non-Hodgkin's lymphoma that has returned or not responded to treatment.
- Your cancer cells have the CD19 or CD22 protein, confirmed by a lab test.
- Your liver, kidney, lung, and heart functions are working well enough.
- You are not pregnant, breastfeeding, or planning to become pregnant for at least a year after treatment.
- You can care for yourself (ECOG score of 0 or 1) and your doctor expects you to live more than 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests a new type of immune cell therapy (CAR-T) that targets two proteins, CD19 and CD20, on your lymphoma cells. It is for people with aggressive B-cell lymphoma that has returned or not responded after several treatments. The goal is to see if this therapy can help shrink the cancer.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target and destroy leukemia or lymphoma cells that carry the CD19 or CD22 marker. It is for people whose cancer has not responded to other treatments or has returned.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that have been modified to find and kill cancer cells with a marker called CD19. It is for adults newly diagnosed with B-cell acute lymphoblastic leukemia or lymphoma who cannot handle strong chemotherapy due to health reasons.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
This trial tests a type of immunotherapy called CAR-T cells that target two proteins (CD19 and CD22) on cancer cells. It may be an option for adults with B-cell acute lymphoblastic leukemia (ALL) or B-cell non-Hodgkin lymphoma (NHL) that has come back or not responded to earlier treatments.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target leukemia cells after chemotherapy has put your disease into remission. The goal is to help prevent the leukemia from coming back, especially for patients at high risk of relapse.
Hear when a new R/R NHL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.